• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Novartis’ Canakinumab Flunks Another Phase III NSCLC Trial

    BIOSPACE

    Novartis looks for silver lining after 2nd Ilaris NSCLC flop

    FIERCEPHARMA

    Strike two for Novartis’ lung cancer antibody canakinumab

    PHARMAPHORUM

    Novartis hits another setback in plan to repurpose rare disease drug

    BIOPHARMADIVE

    Novartis lung cancer drug fails another Phase III trial

    GLOBENEWSWIRE

    Novartis` canakinumab fails to improve survival in lung cancer study

    REUTERS

    Novartis phase III CANOPY-2 study of canakinumab in combo with chemotherapy

    PHARMABIZ

    Novartis’ arthritis therapy shows no efficacy in hospitalised COVID-19 patients

    PHARMAFILE

    Novartis’ CAN-COVID trial of canakinumab in hospitalized patients with COVID-19

    PHARMABIZ

    Novartis Pharms`s Biological Canakinumab Receives Approval In US

    FDA

    Novartis’ Ilaris [canakinumab] unexpectedly slashes need for joint replacements

    FIERCEBIOTECH

    Novartis’ Ilaris cuts rate of joint replacements from arthritis

    FIERCE BIOTECH

    Novartis nabs new FDA approvals for Ilaris and Cosentyx

    PM LIVE

    Novartis` Ilaris first drug approved for Still`s disease

    PHARMATIMES

    FDA Approves First Treatment for Adult Onset Still’s Disease, Rare Disease

    FDA

    Novartis plans COVID-19 testing for Ilaris

    FIERCE PHARMA

    Once again Novartis’ cardio team looks to beat the odds using sketchy data

    ENDPTS

    The top 10 pipeline blowups, setbacks and snafus for H2 2018

    ENDPTS

    Novartis pulls EU filing for canakinumab

    PHARMA TIMES

    Inflazome brings on ex-Novartis executive as CMO after €40M VC round

    FIERCE BIOTECH

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.